Emergent BioSolutions (EBS) Tops Q3 EPS by 32c; Says FY16 Outlook Still Postponed

Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.58, $0.32 better than the analyst estimate of $0.26. Revenue for the quarter came in at $142.9 million versus the consensus estimate of $112.3 million.

The Company continues to postpone its financial guidance for 2016 until the CDC follow-on BioThrax® procurement contract has been finalized.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
• Mizuho Reiterates Neutral Rating on Bloom Energy Corp. (BE)
• JPMorgan Upgrades Wolters Kluwer NV (WKL:NA) (WTKWY) to Overweight